Joint Analysis of Multiple Omics to Describe the Biological Characteristics of Resistant Hypertension

Overview

Journal J Clin Hypertens (Greenwich)

Specialty Cardiology & Vascular Diseases

Date 2024 Dec 24

PMID 39716980

Authors

Shanshan Wang

Yuanlong Hu

Yuqi Wang

Yueyue Song

Dan Liang

Jiufeng Yin

Yunlun Li

Wenqing Yang

Dan Zhang

Affiliations

Soon will be listed here.

Abstract

Resistant hypertension (RH) may cause severe target organ damage and poses significant challenges in the field of hypertension prevention and treatment. Mining biological characteristics is crucial for exploring the pathogenesis of RH and for early diagnosis and treatment. Although several single-omics studies have been conducted on RH, its complex pathogenesis has only been partially elucidated. In this study, metabolomics, proteomics, and transcriptomics were jointly analyzed in healthy subjects and patients with hypertension and RH. The multi-omics analysis found that differential substances of RH were enriched in the HIF-1 signaling pathway and that differential substances such as ascorbic acid, reduced glutathione (GSH), choline, citric acid, transferrin receptor (TfR), Egl-9 family hypoxia-inducible factor 2 (EGLN2), and glutathione peroxidase 1 (GPX1) were screened out. The results of intergroup comparisons were as follows: RH versus N: ascorbic acid (Fold Change (FC):0.42, p < 0.01), GSH (FC:0.65, p < 0.05), choline (FC:1.32, p < 0.05), citric acid (FC:0.48, p < 0.001), TfR (FC2.32, p < 0.001), GPX1 (FC:16.02, p < 0.001), EGLN2 (FC:0.76, p < 0.001); RH versus EH: ascorbic acid (FC:0.52, p < 0.05), GSH (FC:0.55, p < 0.05), choline (FC:1.28, p < 0.05), citric acid (FC:0.59, p < 0.001), TfR (FC:1.71, p < 0.001), GPX1 (FC:2.11, p < 0.05), EGLN2 (FC:0.76, p < 0.05). These differential substances may reflect the biology of RH. This study provides multi-omics analysis for a deeper understanding of the complex molecular characteristics of RH, providing new insights into the pathogenesis, early diagnosis, and precise treatment of the disease.

References

Wang H, Qi Q, Song S, Zhang D, Feng L . Association between soluble transferrin receptor and systolic hypertension in adults: National Health and Nutrition Examination Survey (2007-2010 and 2015-2018). Front Cardiovasc Med. 2022; 9:1029714. PMC: 9671951. DOI: 10.3389/fcvm.2022.1029714. View

Nakamura K, Suzuki Y, Goto K, Yamaguchi S, Hiramitsu M . Antihypertensive and Vasorelaxant Effects of Citric Acid and Lemon Juice in Spontaneously Hypertensive Rats: In Vivo and Ex Vivo Studies. Nutrients. 2023; 15(17). PMC: 10489964. DOI: 10.3390/nu15173849. View

Hartwig S, Czibere A, Kotzka J, Passlack W, Haas R, Eckel J . Combinatorial hexapeptide ligand libraries (ProteoMiner): an innovative fractionation tool for differential quantitative clinical proteomics. Arch Physiol Biochem. 2009; 115(3):155-60. DOI: 10.1080/13813450903154224. View

Van Welden S, Selfridge A, Hindryckx P . Intestinal hypoxia and hypoxia-induced signalling as therapeutic targets for IBD. Nat Rev Gastroenterol Hepatol. 2017; 14(10):596-611. DOI: 10.1038/nrgastro.2017.101. View

Mancia G, Kreutz R, Brunstrom M, Burnier M, Grassi G, Januszewicz A . 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal.... J Hypertens. 2023; 41(12):1874-2071. DOI: 10.1097/HJH.0000000000003480. View

Robaczewska J, Kedziora-Kornatowska K, Kozakiewicz M, Zary-Sikorska E, Pawluk H, Pawliszak W . Role of glutathione metabolism and glutathione-related antioxidant defense systems in hypertension. J Physiol Pharmacol. 2016; 67(3):331-7. View

Piette J, Datwani H, Gaudioso S, Foster S, Westphal J, Perry W . Hypertension management using mobile technology and home blood pressure monitoring: results of a randomized trial in two low/middle-income countries. Telemed J E Health. 2012; 18(8):613-20. PMC: 4361160. DOI: 10.1089/tmj.2011.0271. View

Calhoun D . Hyperaldosteronism as a common cause of resistant hypertension. Annu Rev Med. 2012; 64:233-47. DOI: 10.1146/annurev-med-042711-135929. View

Hwang E, Choi G, Kim K, Kim M, Lee S, Lee J . Vitamin C Lowers Blood Pressure in Spontaneously Hypertensive Rats by Targeting Angiotensin-Converting Enzyme I Production in a Frequency-Dependent Manner. Evid Based Complement Alternat Med. 2022; 2022:9095857. PMC: 9286971. DOI: 10.1155/2022/9095857. View

10.

Schlaich M, Bellet M, Weber M, Danaietash P, Bakris G, Flack J . Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. Lancet. 2022; 400(10367):1927-1937. DOI: 10.1016/S0140-6736(22)02034-7. View

11.

Park S, Shin J, Ihm S, Kim K, Kim H, Kim H . Resistant hypertension: consensus document from the Korean society of hypertension. Clin Hypertens. 2023; 29(1):30. PMC: 10619268. DOI: 10.1186/s40885-023-00255-4. View

12.

Martin-Lorenzo M, Martinez P, Baldan-Martin M, Ruiz-Hurtado G, Prado J, Segura J . Citric Acid Metabolism in Resistant Hypertension: Underlying Mechanisms and Metabolic Prediction of Treatment Response. Hypertension. 2017; 70(5):1049-1056. DOI: 10.1161/HYPERTENSIONAHA.117.09819. View

13.

Maxwell P, Eckardt K . HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond. Nat Rev Nephrol. 2015; 12(3):157-68. DOI: 10.1038/nrneph.2015.193. View

14.

Yugar-Toledo J, Martin J, Krieger J, Pereira A, Demacq C, Coelho O . Gene variation in resistant hypertension: multilocus analysis of the angiotensin 1-converting enzyme, angiotensinogen, and endothelial nitric oxide synthase genes. DNA Cell Biol. 2011; 30(8):555-64. DOI: 10.1089/dna.2010.1156. View

15.

Want E, OMaille G, Smith C, Brandon T, Uritboonthai W, Qin C . Solvent-dependent metabolite distribution, clustering, and protein extraction for serum profiling with mass spectrometry. Anal Chem. 2006; 78(3):743-52. DOI: 10.1021/ac051312t. View

16.

Guo J, Guo X, Sun Y, Li Z, Jia P . Application of omics in hypertension and resistant hypertension. Hypertens Res. 2022; 45(5):775-788. DOI: 10.1038/s41440-022-00885-5. View

17.

Want E, Masson P, Michopoulos F, Wilson I, Theodoridis G, Plumb R . Global metabolic profiling of animal and human tissues via UPLC-MS. Nat Protoc. 2012; 8(1):17-32. DOI: 10.1038/nprot.2012.135. View

18.

Sim J, Bhandari S, Shi J, Reynolds K, Calhoun D, Kalantar-Zadeh K . Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension. Kidney Int. 2015; 88(3):622-32. PMC: 4556588. DOI: 10.1038/ki.2015.142. View

19.

Muda P, Kampus P, Zilmer M, Zilmer K, Kairane C, Ristimae T . Homocysteine and red blood cell glutathione as indices for middle-aged untreated essential hypertension patients. J Hypertens. 2003; 21(12):2329-33. DOI: 10.1097/00004872-200312000-00022. View

20.

Sung J, Lee J, Lee J . Biomarker Differences between Controlled and Uncontrolled Hypertension among US Adults: National Health and Nutrition Examination Survey 2005-2010. Int J Adv Res Sci Eng Technol. 2019; 5(9):6790-6797. PMC: 6715317. View